Sector News

Boston Scientific surges 10% in Q1 amid slew of FDA nods, company reorganization

April 30, 2022
Life sciences

Boston Scientific may have slimmed down its sprawling corporate structure in the first quarter of the year, but that didn’t keep it from plumping up its earnings for the period.

The medtech’s net sales jumped 10% over its performance during the same period last year. The total reached just past the $3 billion threshold, compared to the $2.75 billion it earned in the first three months of 2021.

The jump came even though its earnings sheet for the quarter was short one division compared to the previous year’s. The disparity comes from the sale of Boston Scientific’s BTG specialty pharmaceuticals division, which was completed in March 2021. Until that point, BTG added $13 million that quarter that wasn’t present this time around.

With that and other economic challenges throughout the quarter, the overall increase outdid Boston Scientific’s own expectations. The company had previously set its sights on more modest year-over-year growth, expecting it to clock in somewhere between 5% and 8% on both a reported and an organic basis; in addition to the 10% surge in reported earnings, it tallied its organic growth at 9.7%.

With those higher-than-expected numbers in the rearview, the devicemaker has slightly nudged up its predictions for the full year. Heading into 2022, Boston Scientific aimed to grow between 6% and 8% on a reported basis but now expects growth to fall closer to the 7% to 9% range.

“Our growth this quarter was fueled by strong execution from our global team, our innovative portfolio and improved procedure volume,” said CEO Mike Mahoney. “We are pleased with our first quarter performance and outlook for the full year, despite the impact of macroeconomic headwinds, and we look forward to bringing meaningful innovation to customers and the patients we serve together.”

The sales surge came as Boston Scientific spent the first quarter reorganizing its corporate layout. The end result clustered all of its various medical device businesses under just two headings: medical surgical and cardiovascular.

The restructuring eliminated the rhythm and neuro category. Its cardiac rhythm management and electrophysiology divisions are now housed within the cardiovascular segment—which is split between the cardiology and peripheral interventions departments—while its neuromodulation business was moved to MedSurg, which also encompasses endoscopy, urology and pelvic health.

For the first quarter of the year, the cardiovascular category edged out MedSurg to lead the way in its sales take. It earned $1.87 billion, representing more than 11% growth compared to the same businesses last year, while MedSurg jumped just over 9%, to $1.15 billion, for the period.

The quarter was a busy one for the company. In addition to the internal restructuring, it also landed the FDA’s nod to begin rolling out two new products: a fully retractable coil for arterial and venous embolization procedures and software that improves placement of deep brain stimulation devices in patients with Parkinson’s disease and essential tremor.

Meanwhile, the agency also gave Boston Scientific the go-ahead to begin a clinical trial of its TheraSphere radioactive glass beads, which migrate to the brain to treat recurring tumors.

By Andrea Park

Source: fiercebiotech.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach